| Acceptance rate | 46% |
|---|---|
| Time to first decision | 6 months* |
| Time to decision with review | 50 days* |
*Approximate number of days
**The days mentioned above are averages and do not indicate exact durations. The process may vary for each article.
ACTA Pharmaceutica Sciencia
2024 , Vol 62 , Num 4
The effect of a combination therapy of spironolactone and metformin on women with polycystic ovary syndrome
1 University of Baghdad, Faculty of Medicine, Department of Physiology, Baghdad, Iraq2 Al-Mustafa University College, Faculty of Medicine, Department of Radiology, Baghdad, Iraq
3 Al-Kunooze University College, Faculty of Pharmacy, Basra, Iraq
DOI : 10.23893/1307-2080.APS6249 Viewed : 508 - Downloaded : 117 Many women of childbearing age are affected by polycystic ovary syndrome (PCOS), which is a complex endocrine disorder that has no one ideal treatment. This research aimed to assess the effect of the combination therapy of metformin and spironolactone on the levels of hormones and some PCOS symptoms. This study is a prospective study that conducted on 60 females with PCOS recruited from an Obstetrics and Gynecology private clinic in Baghdad, Iraq, between December 2022 and May 2023 who received a combination therapy of metformin and spironolactone for at least 2 months. Blood samples were taken for the assessment of LH, FSH, and prolactin levels, as well as other PCOS symptoms before and after receiving the treatment for ? 2 months. Results showed that LH and prolactin levels were significantly reduced with a significant decrease in duration of the menstrual cycle absence to approximately 30 days, and a significant reduction in the number of cases that suffer from hirsutism after receiving treatment in comparison with the prevalence of hirsutism before treatment. In conclusion, spironolactone in combination with metformin showed to improve hirsutism and the menstrual cycle frequency as it caused an improvement in the levels of LH, FSH, and prolactin in PCOS patients. Keywords : metformin, polycystic ovary syndrome, spironolactone